Cargando…

Genetically Encoded Fluorescent Sensors for SARS-CoV-2 Papain-like Protease PLpro

In the SARS-CoV-2 lifecycle, papain-like protease PLpro cuts off the non-structural proteins nsp1, nsp2, and nsp3 from a large polyprotein. This is the earliest viral enzymatic activity, which is crucial for all downstream steps. Here, we designed two genetically encoded fluorescent sensors for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sokolinskaya, Elena L., Putlyaeva, Lidia V., Polinovskaya, Vasilisa S., Lukyanov, Konstantin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318946/ https://www.ncbi.nlm.nih.gov/pubmed/35887174 http://dx.doi.org/10.3390/ijms23147826

Ejemplares similares

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
por: Klemm, Theresa, et al.
Publicado: (2020)

Studying SARS-CoV-2 with Fluorescence Microscopy
por: Putlyaeva, Lidia V., et al.
Publicado: (2021)

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach
por: Sencanski, Milan, et al.
Publicado: (2022)

Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes
por: Tan, Jinlin, et al.
Publicado: (2022)

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity
por: Kawall, Anasha, et al.
Publicado: (2023)

SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein–Protein Interactions
por: Ershov, P. V., et al.
Publicado: (2023)

Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro
por: Lewis, Devin S. M., et al.
Publicado: (2022)

Mercapto-pyrimidines are reversible covalent inhibitors of the papain-like protease (PLpro) and inhibit SARS-CoV-2 (SCoV-2) replication
por: Bajaj, Teena, et al.
Publicado: (2023)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies
por: Ali Dahhas, Mohammed, et al.
Publicado: (2023)

Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease
por: Mirza, Muhammad Usman, et al.
Publicado: (2020)

Deubiquitinating Activity of the SARS-CoV Papain-Like Protease
por: Barretto, Naina, et al.
Publicado: (2006)

Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking
por: Castillo-Campos, Luis, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 papain-like protease
por: Gao, Xiaopan, et al.
Publicado: (2021)

Studying Chromatin Epigenetics with Fluorescence Microscopy
por: Stepanov, Afanasii I., et al.
Publicado: (2022)

Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow
por: Parmar, Paritosh, et al.
Publicado: (2021)

A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
por: Patchett, Stephanie, et al.
Publicado: (2021)

In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
por: Huynh, Tien, et al.
Publicado: (2021)

Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2022)

Targeting SARS-CoV-2 papain-like protease in the postvaccine era
por: Ton, Anh-Tien, et al.
Publicado: (2022)

SARS‐CoV‐2 Papain‐Like Protease: Structure, Function and Inhibition
por: Ullrich, Sven, et al.
Publicado: (2022)

Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
por: Ferreira, Glaucio Monteiro, et al.
Publicado: (2022)

Identifying structural–functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation
por: Rao, Priyashi, et al.
Publicado: (2021)

Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV‑2 papain-like protease: Parthenolide covalently inhibits papain-like protease
por: Zou, Zhihui, et al.
Publicado: (2022)

6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities
por: Swaim, Caleb D., et al.
Publicado: (2020)

Inhibitors of SARS-CoV-2 PLpro
por: Calleja, Dale J., et al.
Publicado: (2022)

Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
por: Maiti, Biplab K
Publicado: (2020)

Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors
por: Li, Daoqun, et al.
Publicado: (2021)

In silico analysis of SARS-CoV-2 papain-like protease potential inhibitors
por: Elseginy, Samia A., et al.
Publicado: (2021)

Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease
por: Qiao, Huarui, et al.
Publicado: (2023)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
por: Narayanan, Anoop, et al.
Publicado: (2022)

A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors
por: Yan, Haohao, et al.
Publicado: (2022)

Structural and biochemical characterization of SADS‐CoV papain‐like protease 2
por: Wang, Lu, et al.
Publicado: (2020)

The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)—preliminary molecular docking analysis
por: Marciniec, Krzysztof, et al.
Publicado: (2021)

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
por: Shin, Donghyuk, et al.
Publicado: (2020)

SARS-CoV-2 Papain-Like Protease Potential Inhibitors—In Silico Quantitative Assessment
por: Stasiulewicz, Adam, et al.
Publicado: (2021)

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2
por: Sanders, Brian, et al.
Publicado: (2022)

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
por: Shan, Hengyue, et al.
Publicado: (2021)

Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease
por: Li, Lingyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1fuv42ecc0pa43dh52n2l0hgsf